{"id":924739,"date":"2026-01-07T07:53:24","date_gmt":"2026-01-07T12:53:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-44th-annual-j-p-morgan-healthcare-conference\/"},"modified":"2026-01-07T07:53:24","modified_gmt":"2026-01-07T12:53:24","slug":"dyne-therapeutics-to-present-at-44th-annual-j-p-morgan-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-44th-annual-j-p-morgan-healthcare-conference\/","title":{"rendered":"Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">WALTHAM, Mass., Jan.  07, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ufHaEPYSj74Nt50xiHurXs_daGIQ6YwSGyRBHZRJYZ0OLY-Zgnfj7itDDkFkdDcfAqpeQL5QhTmMVgng_zX_rqDTqD6BN-Flf37NeaiSnpM=\" rel=\"nofollow\" target=\"_blank\"><u>Dyne Therapeutics, Inc<\/u><\/a>. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that John Cox, president and chief executive officer, is scheduled to present at the 44<sup>th<\/sup>\u00a0Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 5:15 p.m. PT (8:15 p.m. ET).<\/p>\n<p>A live webcast will be available in the Investors &amp; Media section of Dyne\u2019s website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=aswnDo0erVftR053RCj5cFuWI7Q-c7zw7qyc8d0jRwottWXyJE8i8dERx99FuwC3uUowpkKC2Nb_eBEGDAbhwlrqh107TuchUMYIBJptqsTT58-ibwLaeyWpFax-eSoA6k_lE6rqVHDzYDCsVVa0ZOdBsYV0CwNNNmp5DsOTCJep-WYcgHISbXjXP9pfIFkq6ocCz61M_XAyl2tvWGgrkg_R9KNnq-fAI_gTnhmbSUQtcN08t70a-YkahVkqSCxGdeQDUArf-58QQ4fA4c6LpKkVubUgh5sjV6C1kZNdN0lc7kh8r05eaKsfl2OaUrwXekjBkEuZky1PgJFCvwdgJKxm0wKgHkQZlMqpSniRrwtbO6DT2TwZ3I20_o7K-fFPfmOOQTbRzblmJx8Xa4nvj1j2pj5Z-KkT_QPUWVt5pXGHvaFJbESpquu1zf727EQUaofHA9m5xInRYvfSe-ADNBL50PRW_zn7UmCqQLYhVpGNUDyV92Q9Ki_-HH4gyBB97yjVbt9BiQMqA_vBUiiRSoItLjeGS85iSaIyNrqK9TO1AKOtApslFR-3HwTNINHviuV3lZ-3VnigUc7b0F_7dKgmheIP-xtIzla7zi4i0TGji1bJGENWo1_6UoSdIkSc4fBHfcpKsGGw5pwd4sgGyKjkgquwwSqHSdGZ7h813x_e5-J2W0rkV-mX0Ogc8-vIPGN9J0UOwevX7kiVyDjBsANd6CVbiyAZ9PWZwmuOGEE9C7C4pDMkUaPbaQxtb5ymExj9OG1st9k_tnftmBY8FkDhWmbJEPCGNAG9Yxg0LRlYooT4nfUEfs9Zy1Iba-Tz_FDSeCAlv6OGJP_pjUyED9IjBoH8cnCqjnkkzOsAzHw=\" rel=\"nofollow\" target=\"_blank\">https:\/\/investors.dyne-tx.com\/news-and-events\/events-and-presentations<\/a>\u00a0and a replay will be accessible for 30 days.<\/p>\n<p>\n        <strong>About Dyne Therapeutics<\/strong><br \/>\n        <br \/>Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=aswnDo0erVftR053RCj5cN4Z_AF36RCSueBArNbgXQCbuNS84Oe5jDA-4G4bfATS-i36TNmIHUbwdcbVWSbDGGyRzjsrM_qN4jG-9k1nP4s=\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.dyne-tx.com\/<\/a>, and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xtkeB4Vqm5semZQ1enenGrkNvMERp4FWK--AEdXzx0zY5d-yn39UtHfWIL3hPlvPKJc-le7_CAMip1FTX4j1hg==\" rel=\"nofollow\" target=\"_blank\">X<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=G5L6h6nN1GlKR5if0DECPgHZ_q86cz9bOfjFESmlHM5aRNRkKl1TZC8e0BlY5LIhw4CyJuY_ibKQQ17FvtJ8k_N9y4UJH479ho_ZdSvbwRE=\" rel=\"nofollow\" target=\"_blank\">LinkedIn\u00a0<\/a>and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zpItitpL3Nnd3nXDw1Ae47_1VA8COHavJVgkX-R7HKDmc_jiSz3fx0pmGUq2VIFIWuGCEDq9fpSIZSQW_EQsjMtnVFksS6wtFXU-E9eVTPA=\" rel=\"nofollow\" target=\"_blank\">Facebook<\/a>.\u00a0\u00a0<\/p>\n<p><strong>Contacts:<\/strong><\/p>\n<p>\n        <strong>Investors<\/strong><br \/>\n        <br \/>Mia Tobias<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VqW4GFY1hlDBsO9ghBTF2TRMb9PzGgO_bhuAJXbAM-ulw0bSKYK3nR_2OLCja27j8HiHBjYFtzZ6OsjfGN_pFA==\" rel=\"nofollow\" target=\"_blank\">ir@dyne-tx.com<\/a><br \/>781-317-0353<\/p>\n<p>\n        <strong>Media<\/strong><br \/>\n        <br \/>Stacy Nartker\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WfA2VhEXUnvaIT21dAQt1siCGArttLUaeDt4M7Te7GD38njIL6y_BtARYHY_V5tLibpWwVB-gz0AJWLh4N_ARqfXVYmCLkm_79dFcyfN-mg=\" rel=\"nofollow\" target=\"_blank\">snartker@dyne-tx.com<\/a><br \/>781-317-1938<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMTE1MSM3MzQ4MTA2IzIyMDA4OTI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZWY0NGJmYmItMjk2YS00OWE4LWEwNjMtMTc5ZGMzNzdiZWM5LTEyMTI0NDUtMjAyNi0wMS0wNy1lbg==\/tiny\/Dyne-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WALTHAM, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) &#8212; Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that John Cox, president and chief executive officer, is scheduled to present at the 44th\u00a0Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 5:15 p.m. PT (8:15 p.m. ET). A live webcast will be available in the Investors &amp; Media section of Dyne\u2019s website at\u00a0https:\/\/investors.dyne-tx.com\/news-and-events\/events-and-presentations\u00a0and a replay will be accessible for 30 days. About Dyne Therapeutics Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-44th-annual-j-p-morgan-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-924739","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-44th-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WALTHAM, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) &#8212; Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that John Cox, president and chief executive officer, is scheduled to present at the 44th\u00a0Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 5:15 p.m. PT (8:15 p.m. ET). A live webcast will be available in the Investors &amp; Media section of Dyne\u2019s website at\u00a0https:\/\/investors.dyne-tx.com\/news-and-events\/events-and-presentations\u00a0and a replay will be accessible for 30 days. About Dyne Therapeutics Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system &hellip; Continue reading &quot;Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-44th-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-07T12:53:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMTE1MSM3MzQ4MTA2IzIyMDA4OTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-44th-annual-j-p-morgan-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-44th-annual-j-p-morgan-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference\",\"datePublished\":\"2026-01-07T12:53:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-44th-annual-j-p-morgan-healthcare-conference\\\/\"},\"wordCount\":219,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-44th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMTE1MSM3MzQ4MTA2IzIyMDA4OTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-44th-annual-j-p-morgan-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-44th-annual-j-p-morgan-healthcare-conference\\\/\",\"name\":\"Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-44th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-44th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMTE1MSM3MzQ4MTA2IzIyMDA4OTI=\",\"datePublished\":\"2026-01-07T12:53:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-44th-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-44th-annual-j-p-morgan-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-44th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMTE1MSM3MzQ4MTA2IzIyMDA4OTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMTE1MSM3MzQ4MTA2IzIyMDA4OTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-44th-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-44th-annual-j-p-morgan-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference - Market Newsdesk","og_description":"WALTHAM, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) &#8212; Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that John Cox, president and chief executive officer, is scheduled to present at the 44th\u00a0Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 5:15 p.m. PT (8:15 p.m. ET). A live webcast will be available in the Investors &amp; Media section of Dyne\u2019s website at\u00a0https:\/\/investors.dyne-tx.com\/news-and-events\/events-and-presentations\u00a0and a replay will be accessible for 30 days. About Dyne Therapeutics Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system &hellip; Continue reading \"Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-44th-annual-j-p-morgan-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-01-07T12:53:24+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMTE1MSM3MzQ4MTA2IzIyMDA4OTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-44th-annual-j-p-morgan-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-44th-annual-j-p-morgan-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference","datePublished":"2026-01-07T12:53:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-44th-annual-j-p-morgan-healthcare-conference\/"},"wordCount":219,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-44th-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMTE1MSM3MzQ4MTA2IzIyMDA4OTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-44th-annual-j-p-morgan-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-44th-annual-j-p-morgan-healthcare-conference\/","name":"Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-44th-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-44th-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMTE1MSM3MzQ4MTA2IzIyMDA4OTI=","datePublished":"2026-01-07T12:53:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-44th-annual-j-p-morgan-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-44th-annual-j-p-morgan-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-44th-annual-j-p-morgan-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMTE1MSM3MzQ4MTA2IzIyMDA4OTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMTE1MSM3MzQ4MTA2IzIyMDA4OTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-44th-annual-j-p-morgan-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/924739","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=924739"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/924739\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=924739"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=924739"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=924739"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}